The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: Dependence on serum LDL levels

doi:10.1016/0021-9150(86)90099-7

Atherosclerosis

Volume 62, Issue 3, December 1986, Pages 249-257

https://doi.org/10.1016/0021-9150(86)90099-7 Get rights and content

Abstract

Lipoprotein(a) concentrations were measured by radial immunodiffusion in a cohort of 40–60 year males who had been classified by coronary angiography as CAD + with 50% stenosis of one or more of the major coronary arteries or CAD — with no signs of coronary lesions. Sample odds ratios were calculated as a measure of association between serum Lp(a) values and the presence of coronary artery disease. An odds ratio of 2.706 (P < 0.001) was derived for elevated (≥ 30 mg/dl) Lp(a) levels vs low ( < 5 mg/dl) Lp(a) levels indicating a strong association between the presence of coronary artery disease and elevated Lp(a) concentrations. This association was independent of the known risk factors smoking, hypertension and diabetes as well as the serum concentrations of total triglycerides, HDL-cholesterol, α-Lp-cholesterol and pre-β-Lp-cholesterol. In contrast to these variables the association between Lp(a) and coronary artery disease was dependent upon the serum concentrations of LDL-cholesterol, β-Lp-cholesterol and total cholesterol. At concentrations below the respective median for each variable, odds ratios of between 1.42 and 1.67 were calculated whereas at concentrations above the respective medians the odds ratios ranged from 4.50 to 6.33 (P < 0.001). Our data, therefore, suggest that increasing LDL concentrations markedly increase the risk of coronary artery disease due to elevated Lp(a) levels.

References (26)

G. Utermann et al.
Protein composition of lp(a) lipoprotein from human plasma
FEBS Letters
(1983)
G.M. Fless et al.
Isolation of apolipoprotein (a) from lipoprotein (a)
J. Lipid Res.
(1985)
J.J. Albers et al.
Lp(a) lipoprotein — Relationship to sinking pre-β-lipoprotein, hyperlipoproteinemia and apolipoprotein B
Metabolism
(1975)
K.W. Walton et al.
A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidemia and atherosclerosis
Atherosclerosis
(1974)
J.J. Albers et al.
Radioimmunoassay of human plasma Lp(a) lipoprotein
J. Lipid Res.
(1977)
M.M. Frick et al.
Serum lipids in angiographically assessed coronary atherosclerosis
Chest
(1978)
G.M. Kostner et al.
Lipoprotein Lp(a) and the risk for myocardial infarction
Atherosclerosis
(1981)
A. Murai et al.
Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction
Atherosclerosis
(1986)
G.W. Gaubatz et al.
Human plasma lipoprotein(a) — Structural properties
J. Biol. Chem.
(1983)
V.W. Armstrong et al.
Isolation, characterization and uptake in human fibroblasts of an apo (a)-free lipoprotein obtained on reduction of lipoprotein(a)
J. Lipid Res.
(1985)

G. Vessby et al.

Diverging effects of cholestyramine on lipoprotein B and lipoprotein Lp(a) — A dose-response study of the effects of cholestyramine in hypercholesterolemia

Atherosclerosis

(1982)

F. Krempler et al.

Turnover of lipoprotein (a) in man

J. Clin. Invest.

(1980)

T.P. Bersot et al.

Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein (a) and that cause lipid accumulation in macrophages

J. Clin. Invest.

(1986)

Cited by (620)

Dyslipidaemia and growth hormone deficiency – A comprehensive review
2023, Best Practice and Research: Clinical Endocrinology and Metabolism
Growth hormone deficiency (GHD) is a common complication of several pituitary and hypothalamic disorders and dependent on the onset of disease. It may have severe clinical implications ranging from growth retardation in childhood-onset, to impaired lipid metabolism and increased cardiovascular risk and mortality in adults. GH effectively modulates lipid metabolism at multiple levels and GHD has been associated with an atherogenic lipid profile, that can be reversed by GH replacement therapy. Despite increasing knowledge on the effects of GH on several key enzymes regulating lipid metabolism and recent breakthroughs in the development and wider availability of recombinant GH preparations, several questions remain regarding the replacement therapy in adults with GHD. This review aims to comprehensively summarize the current knowledge on (i) lipid profile abnormalities in individuals with GHD, (ii) proposed mechanisms of action of GH on lipid and lipoprotein metabolism, and (iii) clinical implications of GH replacement therapy in individuals diagnosed with GHD.
Increase of serum lipoprotein (a), an adverse effect of growth hormone treatment
2022, Growth Hormone and IGF Research
A number of reports show that high endogenous, or therapeutic administration of human growth hormone (hGH) cause an increase of serum lipoprotein a, Lp(a). Being thrombogenic Lp(a) is an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Hence, it is hypothesized that the recently reported association between childhood hGH treatment and cardiovascular morbidity is probably due to the GH effect on Lp(a) synthesis. It is therefore suggested to determine serum Lp(a) levels before and during hGH treatment in children and adults.
Elevated Lipoprotein A in South Asians and the Associated Risk of Cardiovascular Disease: A Systematic Review
2021, Current Problems in Cardiology
Background: South Asians have a premature risk of cardiovascular disease and increased lipoprotein A which enhances their risk. Methods: This systematic review evaluates the role of elevated lipoprotein A in cardiovascular disease risk for South Asians. It discusses the pathophysiology, clinical studies, and treatment of elevated lipoprotein A using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses method. Results: A total of 72 articles was incorporated which consisted of clinical studies, case-control and cohort studies, meta-analysis, reviews, and editorials. Cardiovascular disease and myocardial infarction occurs prematurely in South Asians, which is further enhanced with an elevated lipoprotein A. Conclusions: South Asians with an elevated lipoprotein A have an increased risk of coronary artery disease so they should have early enactment of lifestyle modification and aggressive medical management.
Usefulness of Lipoprotein (a) for Predicting Outcomes After Percutaneous Coronary Intervention for Stable Angina Pectoris in Patients on Hemodialysis
2020, American Journal of Cardiology
Serum lipoprotein (a) level is genetically determined and remains consistent during a person's life. Previous studies have reported that people with high lipoprotein (a) level are at a high risk of cardiac events. We investigated the association between lipoprotein (a) levels and clinical outcomes after percutaneous coronary intervention (PCI) for stable angina pectoris (SAP) in hemodialysis (HD) patients. Serum lipoprotein (a) levels were measured on admission in 410 consecutive HD patients who underwent successful PCI for SAP. Patients were divided into 2 groups: low and high group having lipoprotein (a) level <40 mg/dL (n = 297) and ≧40 mg/dL (n = 113) respectively. After PCI, the incidence of major adverse cardiac event (MACE) including cardiac death, nonfatal myocardial infarction, necessity of a new coronary revascularization procedure (coronary bypass surgery, repeat target lesion PCI, PCI for a new non-target lesion) was analyzed. At a median follow-up of 24 months (12 to 37 months), MACE occurred in 188 patients (45.6%). The rate of MACE rate was significantly higher in the high lipoprotein (a) group than in the low lipoprotein (a) group (59.2% vs 40.7%, long-rank test chi-square = 12.3; p < 0.001). Cox analysis showed that high lipoprotein (a) level (Hazard Ratio, 1.62; 95% Confidence Interval, 1.19 to 2.20; p = 0.002) was an independent predictor for MACE after PCI. In conclusion, high lipoprotein (a) level was associated with a higher incidence of MACE after PCI for SAP in HD patients.
Prevalence of cardiovascular disease risk factors in Tallinn, Estonia
2017, Medicina (Lithuania)
Cardiovascular diseases are still a major public health concern in Estonia despite the decline in the mortality rate during the past decade. For better preventive strategies we aimed to investigate the prevalence of cardiovascular disease risk factors and their relations with age, gender and ethnicity.
The cross-sectional study was carried out in Tallinn, Estonia. Two hundred individuals from each of the sex and 10-year age group (range 20–65 years of age) were randomly selected and invited to participate. Final study sample consisted of 511 men and 600 women (mean age of 46 years). Physiological measurements were taken and blood samples were drawn for standard measurements of the following markers: total cholesterol, high- and low-density lipoprotein cholesterol, apolipoproteins, triglycerides, glucose and inflammatory markers.
Overall, 31% of the study subjects had high blood pressure, 23% had metabolic syndrome, and 55% were overweight/obese. The prevalence of all risk factors increased with age amongst both genders. The proportion of individuals having increased cholesterol, apolipoprotein B-100, and homocysteine levels was very high amongst both genders (60–80%). More Russians and other ethnic minorities compared to ethnic Estonians had calculated 10-year CHD risk ≥ 10%.
The study established a high prevalence of cardiovascular disease risk factors in Estonian adults (20–65 years of age). Younger portion of the population and some extent ethnic considerations should be taken into account when designing future studies, health prevention activities and interventions.
Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology
2016, Journal of Lipid Research
Citation Excerpt :
Corresponding odd ratios were 1.7 (95% CI: 1.2–2.5) for carotid atherosclerotic stenosis (Fig. 8, middle panel) and 1.6 (95% CI: 1.3–2.0) for femoral atherosclerotic stenosis (Fig. 8, bottom panel). Many other studies have also found an association between high concentrations of Lp(a) or LPA risk genotypes and high risk of coronary, carotid, and femoral atherosclerotic stenosis (101, 102, 121, 160, 189–207). For example, in a cohort of 504 patients, Sam Tsimikas, Joe Witztum, and colleagues showed a strong association between high oxidized phospholipids and high Lp(a) concentrations with the presence and extent of coronary artery disease, detected by coronary angiography as the number of vessels with a stenosis of more than 50% of the luminal diameter (190).
Human epidemiologic and genetic evidence using the Mendelian randomization approach in large-scale studies now strongly supports that elevated lipoprotein (a) [Lp(a)] is a causal risk factor for cardiovascular disease, that is, for myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis. The Mendelian randomization approach used to infer causality is generally not affected by confounding and reverse causation, the major problems of observational epidemiology. This approach is particularly valuable to study causality of Lp(a), as single genetic variants exist that explain 27–28% of all variation in plasma Lp(a). The most important genetic variant likely is the kringle IV type 2 (KIV-2) copy number variant, as the apo(a) product of this variant influences fibrinolysis and thereby thrombosis, as opposed to the Lp(a) particle per se. We speculate that the physiological role of KIV-2 in Lp(a) could be through wound healing during childbirth, infections, and injury, a role that, in addition, could lead to more blood clots promoting stenosis of arteries and the aortic valve, and myocardial infarction. Randomized placebo-controlled trials of Lp(a) reduction in individuals with very high concentrations to reduce cardiovascular disease are awaited. Recent genetic evidence documents elevated Lp(a) as a cause of myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis.

View all citing articles on Scopus

^∗: Present address: ISB, Klinikum Grosshadern, Marchioninstrasse 15, D-8000 Munich 70, F.R.G.

^∗∗: Present address: Zentrallabor am Uniklinikum, Hugstetterstr. 55, D-7800 Freiburg, F.R.G.

View full text

Research paperThe association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: Dependence on serum LDL levels

Abstract

FEBS Letters

J. Lipid Res.

Metabolism

Atherosclerosis

J. Lipid Res.

Chest

Atherosclerosis

Atherosclerosis

Human plasma lipoprotein(a) — Structural properties

J. Biol. Chem.

Isolation, characterization and uptake in human fibroblasts of an apo (a)-free lipoprotein obtained on reduction of lipoprotein(a)

J. Lipid Res.

Diverging effects of cholestyramine on lipoprotein B and lipoprotein Lp(a) — A dose-response study of the effects of cholestyramine in hypercholesterolemia

Atherosclerosis

Turnover of lipoprotein (a) in man

J. Clin. Invest.

Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein (a) and that cause lipid accumulation in macrophages

J. Clin. Invest.

Research paper
The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: Dependence on serum LDL levels